SCHEMBL533755

SCHEMBL533755

CCCCCCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCOC1(OCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCCCCCC)C=CC(C(O)c2ccccc2)=CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
ALOX5 P09917 1/20 0.35
LMNA P02545 1/20 0.35
NAAA Q02083 2/20 0.33
OPRM1 P35372 2/20 0.33
OPRD1 P41143 2/20 0.33
OPRK1 P41145 2/20 0.33
OPRL1 P41146 2/20 0.33
NR5A1 Q13285 1/20 0.32
ALDH1A1 P00352 2/20 0.32
KMT2A Q03164 2/20 0.32
ASAH1 Q13510 2/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
MEN1 O00255 1/20 0.32
RECQL P46063 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9007079 0.77 NAAA (0.42) SMN1; SMN2NPC1RAB9ALMNANAAA
SCHEMBL533892 0.76 TSHR (0.36) LMNANAAAALDH1A1TSHR
SCHEMBL10596280 0.72 NR5A1 (0.38) NR5A1KMT2ACYP2C9CYP2C19MEN1
SCHEMBL31215183 0.70 CYP2C9 (0.34) LMNANR5A1ALDH1A1KMT2ACYP2C9
SCHEMBL9403662 0.69 PTPN11 (0.49) LMNAOPRK1ALDH1A1KMT2ACYP2C9
SCHEMBL31215181 0.68 CHRNA7 (0.33) NR5A1ALDH1A1KMT2ACYP2C9CYP2C19
SCHEMBL8906187 0.68 SLC6A3 (0.36) KMT2AMEN1
SCHEMBL29001824 0.67 NR5A1 (0.33) NR5A1KMT2ACYP2C9CYP2C19MEN1
SCHEMBL10883785 0.66 MEN1 (0.37) SMN1; SMN2ALDH1A1KMT2ACYP2C9MEN1
SCHEMBL11158758 0.65 SMN1; SMN2 (0.56) SMN1; SMN2NPC1RAB9ALMNANAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9670121-B2 Diphenylmethane compound AJINOMOTO CO., INC. (JP) 2017-06-06 US claimed
US-20160060198-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC. (JP) 2016-03-03 US claimed
US-9169187-B2 Method of making peptides using diphenylmethane compound AJINOMOTO CO., INC. (JP) 2015-10-27 US claimed
US-20140213761-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC (JP) 2014-07-31 US claimed
EP-2415745-A1 DIPHENYLMETHANE COMPOUND Ajinomoto Co., Inc. (JP) 2012-02-08 EP claimed
US-20100249374-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC. (JP) 2010-09-30 US claimed
WO-2025122535-A2 LIQUID PHASE PEPTIDE SYNTHESIS METHODS AMGEN INC. (US) 2025-06-12 WO disclosed
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS AMGEN INC. (US) 2025-06-12 US disclosed
EP-3412689-B1 HYDROGENATED BLOCK-COPOLYMER HAVING ACID ANHYDRIDE GROUP AND USE THEREOF ZEON CORP (JP) 2020-10-14 EP disclosed
US-20190203035-A1 BLOCK-COPOLYMER HYDRIDE HAVING ACID ANHYDRIDE GROUP AND USE THEREOF ZEON CORPORATION (JP) 2019-07-04 US disclosed
EP-3412689-A1 BLOCK-COPOLYMER HYDRIDE HAVING ACID ANHYDRIDE GROUP AND USE THEREOF Zeon Corporation (JP) 2018-12-12 EP disclosed
US-20180086029-A1 RESIN COMPOSITION AND USE OF SAME ZEON CORPORATION (JP) 2018-03-29 US disclosed
EP-3281981-A1 RESIN COMPOSITION AND USE OF SAME Zeon Corporation (JP) 2018-02-14 EP disclosed
US-9670121-B2 Diphenylmethane compound AJINOMOTO CO., INC. (JP) 2017-06-06 US disclosed
US-20160060198-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC. (JP) 2016-03-03 US disclosed
US-9169187-B2 Method of making peptides using diphenylmethane compound AJINOMOTO CO., INC. (JP) 2015-10-27 US disclosed
US-20140213761-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC (JP) 2014-07-31 US disclosed
US-8722934-B2 Diphenylmethane compound AJINOMOTO CO., INC. (JP) 2014-05-13 US disclosed
EP-2415745-A1 DIPHENYLMETHANE COMPOUND Ajinomoto Co., Inc. (JP) 2012-02-08 EP disclosed
US-20100249374-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC. (JP) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249374-A1 DIPHENYLMETHANE COMPOUND CCKAR, DNPEP, QPCTL SMN1; SMN2 2836/4885NPC1 2869/4885RAB9A 4762/4885
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS VIP, RNGTT, SSU72 SMN1; SMN2 2212/4885NPC1 2397/4885RAB9A 4009/4885
US-20140213761-A1 DIPHENYLMETHANE COMPOUND CCKAR, VIP, CCKBR SMN1; SMN2 2691/4885NPC1 2111/4885RAB9A 4622/4885
US-20160060198-A1 DIPHENYLMETHANE COMPOUND CCKAR, VIP, CCKBR SMN1; SMN2 2691/4885NPC1 2111/4885RAB9A 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.